Cannabinoids may ease withdrawal symptoms, but not stop addiction
Cannabinoid exposure across substance use disorders: Short-term symptom benefits without sustained therapeutic gains in a tier-weighted systematic review.
AI Summary
This systematic review examined whether cannabinoid exposure helps treat substance use disorders involving opioids, alcohol, cocaine, tobacco, and methamphetamine. Across 97 studies involving 41,954 participants, the review assessed treatment retention, relapse, abstinence, craving, withdrawal severity, and consumption. Overall, the evidence was mixed: beneficial results were reported more often for short-term symptoms than for lasting recovery outcomes.
The review found that 76.4% of beneficial findings involved short-term symptom relief, such as reduced craving or withdrawal severity. However, sustained outcomes—including abstinence, relapse prevention, and treatment retention—were generally not improved, with this pattern most pronounced in opioid use disorder. Because many positive symptom findings came from weaker study designs, the authors conclude that cannabinoids may provide short-horizon relief but have not demonstrated sustained therapeutic benefits. Stronger randomized trials with objectively verified outcomes are needed.
💡 Key Findings
📄
Original Abstract
Related Research
Similar Studies
More Addiction research papers you might find interesting.
EEG profiles recurred across groups, but individual reliability was low
A proposed risk-factor approach links cannabis use and other exposures to…
Umbrella review links frequent cannabis use with psychosis risk
Explore More Research
Stay informed about the latest cannabis science.